Grifols SA (GRFS) AI Stock Analysis

• Market Cap: $7.20B
• Dividend Yield: 1.69%
• Average Volume (3M): 713.33K
• Price to Earnings (P/E): 13.7
• Beta (1Y): 0.80
• Revenue Growth: 9.45%
• EPS Growth: 167.00%
• Country: US
• Employees: 23,833
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 0.21
• Shares Outstanding: 261,425,100
• 10 Day Avg. Volume: 1,041,396
• 30 Day Avg. Volume: 713,328
• PEG Ratio: 0.19
• Price to Book (P/B): 0.83
• Price to Sales (P/S): 0.68
• P/FCF Ratio: 9.20
• Enterprise Value/Market Cap: 2.81
• Enterprise Value/Revenue: 2.69
• Enterprise Value/Gross Profit: 6.81
• Enterprise Value/Ebitda: 12.85
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 0.88
• Revenue Forecast (FY): $8.71B

• Rating: 65 Neutral
• Price Target: $10.00 ▲(4.71% Upside)

Grifols SA's overall stock score reflects strong financial performance and positive earnings call sentiment, offset by high leverage and bearish technical indicators. The company's valuation is fair, but not compelling. Continued focus on improving margins and managing leverage is crucial for future stability.

Grifols SA Business Overview & Revenue Model

Company Description

Grifols SA (GRFS) is a global healthcare company based in Spain that specializes in the production of plasma-derived medicines, with a focus on treating rare and chronic diseases. The company operates in three main segments: Bioscience, Diagnostic, and Hospital. Grifols is renowned for its innovative therapies, including immunoglobulins, albumin, and clotting factors, which are primarily used to treat patients with immune deficiencies, blood disorders, and other conditions.

How the Company Makes Money

Grifols generates revenue primarily through the sale of its plasma-derived products, which are a significant portion of its revenue. The company operates a robust network of human plasma collection centers, which allows it to secure a steady supply of plasma for its manufacturing processes. Key revenue streams include sales from its Bioscience division, which provides therapies for patients with immune deficiencies and other chronic conditions. Additionally, Grifols earns revenue from its Diagnostic and Hospital segments, which offer a range of products and services for hospitals and laboratories. The company has established significant partnerships with healthcare institutions and organizations, enhancing its market reach and facilitating the distribution of its products. Factors contributing to Grifols' earnings include the increasing demand for blood products globally, advancements in biotechnology, and the company's commitment to research and development, which drives innovation and the introduction of new therapies.

Grifols SA Financial Statement Overview

Summary

Grifols SA shows strong revenue growth and improved operating margins, but struggles with a low net profit margin. The balance sheet reveals high leverage, requiring careful management. Strong cash flow generation is positive, yet further enhancement is needed to bolster financial stability.

Income Statement

Grifols SA demonstrates strong revenue growth with a 9.41% increase from 2023 to 2024. The gross profit margin improved to 38.74%, indicating efficient cost management. However, the net profit margin remains relatively low at 2.18%, suggesting potential cost or operational inefficiencies. The EBIT margin increased to 16.53%, reflecting better operating performance.

Balance Sheet

The debt-to-equity ratio of 1.71 indicates a high level of leverage, which could pose risks if not managed properly. Return on equity is modest at 2.67%, suggesting room for improvement in profitability. The equity ratio of 27.49% highlights a stable asset base supported by equity, though there is reliance on debt.

Cash Flow

Grifols SA shows a significant improvement in free cash flow, turning positive in 2024. The operating cash flow to net income ratio of 5.75 reflects strong cash generation capacity relative to net profits. However, the free cash flow to net income ratio of 3.38 indicates that cash flow improvements are still needed to enhance financial flexibility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.52B	7.21B	6.59B	6.06B	4.93B	5.34B
Gross Profit	2.97B	2.79B	2.48B	2.21B	1.96B	2.26B
EBITDA	1.57B	1.48B	1.17B	1.19B	944.03M	1.42B
Net Income	372.72M	156.92M	42.32M	185.03M	188.73M	618.55M
Balance Sheet
Total Assets	19.85B	21.41B	20.99B	21.23B	19.23B	15.27B
Cash, Cash Equivalents and Short-Term Investments	825.48M	1.00B	646.04M	580.24M	2.69B	590.51M
Total Debt	1.08B	10.09B	11.02B	0.00	10.17B	6.91B
Total Liabilities	12.31B	12.80B	13.48B	13.25B	11.92B	8.55B
Stockholders Equity	5.18B	5.88B	5.37B	5.65B	5.52B	5.11B
Cash Flow
Free Cash Flow	851.18M	530.80M	-91.63M	-386.43M	349.60M	830.18M
Operating Cash Flow	1.13B	902.17M	218.69M	-10.87M	596.98M	1.11B
Investing Cash Flow	-605.99M	886.67M	-394.72M	-1.98B	-854.15M	-858.12M
Financing Cash Flow	-480.99M	-1.36B	171.49M	-173.49M	2.30B	-354.40M

Grifols SA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 9.55
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRFS, the sentiment is Negative. The current price of 9.55 is above the 20-day moving average (MA) of 9.31, below the 50-day MA of 9.61, and above the 200-day MA of 8.61, indicating a bearish trend. The MACD of -0.27 indicates Positive momentum. The RSI at 28.22 is Positive, neither overbought nor oversold. The STOCH value of 8.81 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GRFS.

Grifols SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GILD	77 Outperform	$147.46B	18.42	40.62%	2.62%	2.71%	6407.19%
GSK	77 Outperform	$93.52B	13.12	35.62%	3.59%	5.97%	128.66%
AMGN	77 Outperform	$169.94B	24.40	81.71%	3.15%	11.03%	65.22%
SNY	76 Outperform	$120.52B	12.35	8.39%	4.45%	-9.32%	120.62%
BMY	69 Neutral	$94.93B	15.75	33.84%	5.31%	1.26%	―
GRFS	65 Neutral	$7.20B	13.74	6.93%	1.69%	9.45%	167.00%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Grifols SA Corporate Events

Grifols Reports Strong Q3 2025 Financial Performance with Biopharma Growth

On November 4, 2025, Grifols reported its third-quarter financial results, highlighting a 9.1% year-over-year revenue increase to EUR 1,865 million, driven by the Biopharma business. The company achieved a group profit of EUR 127 million for the quarter, contributing to a 245% year-to-date profit increase. Grifols also improved its leverage ratio to 4.2x and maintained robust liquidity of EUR 1,475 million. The company continues to focus on free cash flow generation and strategic market positioning, with its immunoglobulin franchise showing significant growth.

Grifols Establishes Strategy Committee to Enhance Strategic Governance

On September 25 and 26, 2025, Grifols, S.A.’s Board of Directors resolved to establish a Strategy Committee to assist in strategic initiatives and developments. The committee, composed of independent, external, and proprietary members, aims to provide advisory support and proposals to the Board. This move is part of Grifols’ efforts to strengthen its strategic governance and enhance its operational efficiency, potentially impacting its market positioning and stakeholder relations.